WO2019066620A3 - 항 c-met 항체 및 이의 용도 - Google Patents

항 c-met 항체 및 이의 용도 Download PDF

Info

Publication number
WO2019066620A3
WO2019066620A3 PCT/KR2018/011644 KR2018011644W WO2019066620A3 WO 2019066620 A3 WO2019066620 A3 WO 2019066620A3 KR 2018011644 W KR2018011644 W KR 2018011644W WO 2019066620 A3 WO2019066620 A3 WO 2019066620A3
Authority
WO
WIPO (PCT)
Prior art keywords
met
same
circulating tumor
antibody
antibodies
Prior art date
Application number
PCT/KR2018/011644
Other languages
English (en)
French (fr)
Other versions
WO2019066620A2 (ko
Inventor
신영기
이지혜
김영덕
이재구
이훈석
Original Assignee
서울대학교산학협력단
주식회사 지노바이오
에이비온 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 서울대학교산학협력단, 주식회사 지노바이오, 에이비온 주식회사 filed Critical 서울대학교산학협력단
Publication of WO2019066620A2 publication Critical patent/WO2019066620A2/ko
Publication of WO2019066620A3 publication Critical patent/WO2019066620A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N35/00—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor
    • G01N35/0098—Automatic analysis not limited to methods or materials provided for in any single one of groups G01N1/00 - G01N33/00; Handling materials therefor involving analyte bound to insoluble magnetic carrier, e.g. using magnetic separation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

본 발명은 항 c-Met 항체 및 이의 용도에 관한 것으로, 보다 상세하게는 인간 유래 c-Met 단백질에 특이적으로 결합하는 항체 또는 그 단편, 이의 생산방법, 이를 이용한 c-Met 특이적 검출 방법, 이를 이용한 순환암세포 (Circulating Tumor Cell, CTC) 검출 방법 및 이를 유효성분으로 포함하는 순환암세포 검출용 키트에 관한 것이다. 본 발명의 방법은 c-Met 항체를 검출하고, 항체를 이용하여 혈액 내의 순환암세포를 검출하는 데에 유용하게 이용될 수 있다.
PCT/KR2018/011644 2017-09-29 2018-10-01 항 c-met 항체 및 이의 용도 WO2019066620A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170128287A KR20190038174A (ko) 2017-09-29 2017-09-29 항 c-Met 항체 및 이의 용도
KR10-2017-0128287 2017-09-29

Publications (2)

Publication Number Publication Date
WO2019066620A2 WO2019066620A2 (ko) 2019-04-04
WO2019066620A3 true WO2019066620A3 (ko) 2019-08-08

Family

ID=65903559

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/011644 WO2019066620A2 (ko) 2017-09-29 2018-10-01 항 c-met 항체 및 이의 용도

Country Status (2)

Country Link
KR (1) KR20190038174A (ko)
WO (1) WO2019066620A2 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
MX2022002886A (es) 2019-09-16 2022-04-06 Regeneron Pharma Proteinas de union met radiomarcadas para la obtencion de imagenes por inmuno-pet.
WO2023204625A1 (ko) * 2022-04-20 2023-10-26 에이비온 주식회사 C-met 발현 ctc를 이용한 유방암 환자의 예후 예측 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014530201A (ja) * 2011-09-20 2014-11-17 イーライ リリー アンド カンパニー 抗ｃ−Ｍｅｔ抗体
KR20160017918A (ko) * 2014-08-07 2016-02-17 주식회사 파멥신 c-Met 특이적 인간 항체 및 그 제조방법
KR20160037667A (ko) * 2014-09-29 2016-04-06 삼성전자주식회사 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014530201A (ja) * 2011-09-20 2014-11-17 イーライ リリー アンド カンパニー 抗ｃ−Ｍｅｔ抗体
KR20160017918A (ko) * 2014-08-07 2016-02-17 주식회사 파멥신 c-Met 특이적 인간 항체 및 그 제조방법
KR20160037667A (ko) * 2014-09-29 2016-04-06 삼성전자주식회사 폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
COMOGLIO, P. M.: "Drug development of MET inhibitors: targeting oncogene addiction and expedience", NAT. DRUG DISCOV., 30 June 2008 (2008-06-30), pages 504 - 516, XP002565003, doi:10.1038/nrd2530 *
ZHANG, T.: "Development of a Novel c-MET-Based CTC Detection Platform", MOL. CANCER RES., 7 March 2016 (2016-03-07), pages 539 - 547, XP055623498 *

Also Published As

Publication number Publication date
WO2019066620A2 (ko) 2019-04-04
KR20190038174A (ko) 2019-04-08

Similar Documents

Publication Publication Date Title
EA201891983A1 (ru) Комбинированная терапия антителами к cd73
SA522432917B1 (ar) ميوتينات إنترليوكين-21 وطرق العلاج
MX2018009011A (es) Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos.
EA201690617A1 (ru) Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей
WO2014183066A3 (en) Protein modification of living cells using sortase
WO2013022953A3 (en) Biomarker for alzheimer's disease and/or mild cognitively impairment, and use thereof
WO2012054929A3 (en) Use of human serum albumin to decrease antigenicity of therapeutic proteins
WO2019066620A3 (ko) 항 c-met 항체 및 이의 용도
EA201070553A1 (ru) Антитела к гепцидину и варианты их применения
WO2012064792A3 (en) Protein complexes for antigen binding and methods of use
WO2014036495A3 (en) Diagnostic assays and kits for detection of folate receptor 1
WO2019066617A3 (ko) 항 c-met 항체 및 이의 용도
WO2013043933A3 (en) Cd27l antigen binding proteins
WO2019060750A3 (en) A33 antibody compositions and methods of using the same in radioimmunotherapy
EA201170312A1 (ru) Селективные антитела к гепцидину-25 и их применение
NZ609824A (en) Immunochromatography devices, methods and kits
AU2017248682A1 (en) Method for detecting and/or characterising tumour cells and associated apparatus
MX2019012461A (es) Anticuerpo anti-pd-l1 y uso del mismo.
WO2016154623A3 (en) Anti-cd133 monoclonal antibodies and related compositions and methods
MX2020009879A (es) Anticuerpos anti-il-27 y sus usos.
MX2021006980A (es) Anticuerpos anti-il-27 y usos de estos.
ZA201907371B (en) Methods and compositions for treating allergic ocular diseases
WO2019094533A8 (en) Angptl8-binding agents and methods of use thereof
WO2017100663A8 (en) Improved methods for treating her2-positive breast cancer
WO2014165710A3 (en) Gene fusions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18861795

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18861795

Country of ref document: EP

Kind code of ref document: A2